SK Bioscience Archives | Page 4 of 4

Home / Posts tagged SK Bioscience (Page 4)

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

GAITHERSBURG, Md., Feb. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and [...]

Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate

GAITHERSBURG, Md. and SEOUL, South Korea, Aug. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for [...]

SK Bioscience, AstraZeneca Sign Deal on COVID-19 Vaccine Supply

SEOUL, July 21 (Korea Bizwire) — South Korea’s SK Bioscience inked a deal with global pharmaceutical company AstraZeneca to supply a candidate material for a coronavirus vaccine, the local biotech company said Tuesday. The letter of intent (LOI) reached between the two companies and the Ministry of Health and Welfare calls for close cooperation on [...]

Bill & Melinda Gates Foundation Invests in S. Korean Companies Developing Virus Vaccine

SEOUL, May 19 (Korea Bizwire) – South Korean companies have received funds from the Bill & Melinda Gates Foundation, one of the world’s largest private foundations, to research treatment for COVID-19 after South Korea became a model case in containing the pandemic, with high potential in the information technology (IT) and biopharma industries. SK Bioscience, a local [...]